The Peak Center houses four programs aimed at providing tumor-specific clinical care and research while fostering interdisciplinary collaboration.
The Brain Metastasis Initiative treats patients who have cancer from other areas of the body that has spread to the brain and spine. It combines minimally invasive surgery with focused stereotactic radiation and medical oncology to reduce deaths from intracranial metastases. All brain tumor patients are offered personalized and aggressive treatment plans comprising surgery, medical oncology and/or focused radiation therapy. Novel technology has revolutionized the care for these patients, and in most cases, we can control the cancer that has spread to the brain for many years. These interventions are, for the most part, minimally invasive and function sparing.
The Pituitary Disorders Program focuses on aggressive treatment protocols, including dopamine agonists, somatostatin analogs, minimally invasive endoscopic surgery and stereotactic radiosurgery for patients with pituitary tumors and disorders. A treatment team composed of neuro-endocrinologists and neurosurgeons, in consultation with radiation oncologists when indicated, work together to construct individualized treatment plans to ensure optimal results. We have experience with minimally invasive surgery in over 3,500 patients, with success rates higher than anywhere else in Houston and with complications rates of less than 1 percent.
Our surgeons have pioneered many of the minimally invasive techniques utilized in these procedures, and most patients stay in the hospital for only 24 to 48 hours. Using a multimodality approach, our cure rate and rate of control of these tumors is over 95 percent. Our patients go on to enjoy productive lives and careers, with minimal disruption from treatment.
The Glial Tumor Treatment Program focuses on compassionate, intensive and aggressive treatment plans, including minimally invasive surgery. Personalized treatment plans based on DNA and genomic analyses, high-throughput drug screening and proteomics will be provided for each patient.
Each patient’s tumor undergoes intense study after it is removed. In addition to standard analyses, we will analyze each tumor by examining all of the known genes in each specimen, and then determining which genes are defective or altered in a way that might cause the cancer. This information will be combined with the results of testing each tumor against every chemotherapeutic agent available in the United States. This information is synthesized, and an individual treatment plan is constructed based on state-of-the-art scientific information from each patient’s tumor.
The Meningioma and Skull Base Tumor Program provides aggressive, state-of-the-art minimally invasive surgery coupled with focused stereotactic radiosurgery and genomic analysis. Its aim is to spare neurological function by harnessing the interdisciplinary resources of neurosurgery, radiation oncology, otorhinolaryngology, neuropathology and neuroradiology.